www.fdanews.com/articles/120857-companies-present-phase-ii-data-on-perifosine
Companies Present Phase II Data on Perifosine
September 29, 2009
AEterna Zentaris announced that Keryx Biopharmaceuticals, its partner and licensee for perifosine in the North American market, reported updated clinical results from a Phase II study of perifosine, the Company's PI3K/Akt pathway inhibitor for cancer, as a single-agent treatment for advanced metastatic renal cell carcinoma.
StreetInsider
StreetInsider